Conatumumab

N/A

Report date: 2025/02/05 20:00:53

Base Information

Drug NameConatumumab
Drug Alias Nameconatumumabum可那木单抗考那妥木单抗AMG-655
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor receptor superfamily member 10B agonistsCaspase stimulantsApoptosis inducers
TargetsTumor necrosis factor receptor superfamily member 10BCaspase
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporePoland +[10] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteAmgen IncNantcell Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[12] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG